AstraZeneca will earn up to $400 million from Takeda after making a deal to co-develop an early-stage medicine for Parkinson’s disease with the Japanese company. The drug, MEDI1341, is an antibody treatment that will begin Phase I clinical trials this year.
AstraZeneca will lead Phase I testing while Takeda will lead future clinical development, per the agreement. The companies will equally share future development and commercialization costs as well as revenues for the med.
Earlier this week, AstraZeneca also partnered with Berg to use AI to work on Parkinson’s disease.
Read the Reuters report